Global Genome Editing Market Insights Forecasts to 2033

• The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023
• The Market Size is Growing at a CAGR of 16.19% from 2023 to 2033
• The Worldwide Genome Editing Market Size is Expected to Reach USD 34.75 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

Get more details on this report -

Request Free Sample PDF

The Global Genome Editing Market Size is Anticipated to Exceed USD 34.75 Billion by 2033, Growing at a CAGR of 16.19% from 2023 to 2033.

 

Market Overview

The technique known as "genome editing" enables researchers to alter the DNA of a wide range of creatures, including bacteria, plants, and mammals. Health risks and physical characteristics, such as eye color, might change as a result of DNA editing. Various technologies are employed by scientists for this purpose. Researchers can alter physical characteristics, such as eye color and illness risk, by modifying DNA via the use of genome editing technology. Various technologies are used by scientists for this purpose. These technologies operate at a specific location in the DNA, cutting it like scissors. Then, where the DNA was sliced, scientists can add, reduce, or replace it. Any organism's genome might be changed with it. When a specific section of DNA is damaged, the cell repairs it on its own. It might be used in a number of industries, including biotechnology, agriculture, medicine, and genetics. The use of genome editing will likely expand as infectious and chronic illnesses become more common. The market participants' increasing competitiveness for company development, the success of preclinical models driving demand for genome editing treatments, the development of gene editing technologies, and the growing use of agricultural biotechnology are all responsible for this increase.

 

Report Coverage

This research report categorizes the market for the global genome editing market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global genome editing market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global genome editing market.

 

Driving Factors

A growing number of genetic illnesses and abnormalities are being caused by genome editing technology. A current area of study for scientists and pharmaceutical companies is the creation of possible treatments for genetic disorders. Commercialization and development of genome editing technologies have been aided by increased funding in biotechnology and healthcare. Research projects, clinical trials, and the creation of therapeutic interventions based on lab results can all be funded by donations to universities. Genome editing has made a significant contribution to personalized medicine: treating patients according to their unique genetic composition. This strategy can reduce negative effects while increasing treatment effectiveness. In agriculture, genetic engineering is being utilized to create more nutrient-dense, disease- and pest-resistant crops with higher yields. With this application, food security and sustainable agriculture might be enhanced. The industry is expanding due to favorable government rules around synthetic biology, increased government and major company investments, and the growing demand for altered genes and cells. Another important development in gene therapy and molecular biology that has aided in the market's expansion is the creation and application of several novel gene editing techniques. 

 

Restraining Factors

Two main barriers to the genome editing business are the lengthy approval processes that regulatory bodies use to approve genetically modified items and the pervasive misinformation that exists about these products. The effects of CRISPR-off-target Cas9 are an important concern. Cas9 encourages double-strand breaks as a consequence, and any off-target nuclease activity might cause these genes to mutate and perhaps cause oncogenesis. Up to three target mismatches that CRISPR-Cas9 can withstand will cause off-target nuclease activity. The 50% incidence of off-target activity or alterations at places other than the targeted on-target site is also quite concerning. For example, CRISPR might target the gene that causes cancer or the tumour suppressor gene. Several organizations preparing clinical trials have faced challenges as a result of this unexpected impact. Clinical trials have been put on hold, and regulatory bodies are requesting more studies to increase the safety of the procedure. In the upcoming years, it is anticipated that the high cost of genomic equipment and ethical issues surrounding genetic research will impede industry progress.

 

Market Segmentation

The global genome editing market share is classified into technology, delivery method, application, mode.

 

• The CRISPR/Cas9 segment is expected to hold the largest share of the global genome editing market during the forecast period.   

Based on the technology, the global genome editing market is divided into CRISPR/Cas9, TALENs/MegaTALs, ZFN, Mega nuclease, and others. Among these, CRISPR/Cas9 segment is expected to hold the largest share of the global genome editing market during the forecast period. High accuracy and efficiency, great flexibility in various experimental designs, and cost-effectiveness with minimal related costs are the reasons behind this. Over the course of the projected period, it is also expected that demand for CRISPR will increase due to the expanding number of applications. The clinical uses of CRISPR are generally acknowledged. This is demonstrated by the growing number of active clinical trials that use gene-editing methods to treat a variety of illnesses, including cancer, AIDS, and hereditary disorders. Applications of this technology in agricultural and animal breeding are growing in addition to its use in human health.

 

• The ex-vivo is expected to hold the largest share of the global genome editing market during the forecast period.   

Based on the delivery mode, the global genome editing market is divided into ex-vivo and in-vitro. Among these, the ex-vivo segment is expected to hold the largest share of the global genome editing market during the forecast period. This dominance can be linked to the careful manipulation of nuclease expression strength and duration to reduce off-target editing and increase efficiency, as well as the ease with which DNA modification can be controlled. It is noted that in the therapeutic molecular scissors pipeline, ex-vivo products like CAR-T technology for cancer blood treatment are given priority.  

 

• The genetic engineering segment is expected to hold the largest share of the global genome editing market during the forecast period.   

Based on the application, the global genome editing market is divided into genetic engineering and clinical applications. Among these, the genetic engineering segment is expected to hold the largest share of the global genome editing market during the forecast period. Plant genetic engineering, animal genetic engineering, cell line engineering, and other categories are further divided into this section. It is projected that the application of gene therapy to create new molecules for the treatment of illnesses such as sickle cell disease, lymphoma, and infectious disorders will increase acceptance by the end of the projection period.

 

• The contract segment is expected to hold the largest share of the global genome editing market during the forecast period.

Based on the mode, the global genome editing market is divided into contract and in-house. Among these, the contract segment is expected to hold the largest share of the global genome editing market during the forecast period. The growing strategic efforts that outsourcing service providers are doing are expected to fuel additional expansion in the market. For example, in December 2022, Crown Bioscience, Inc., a CRO, partnered with ERS Genomics Limited to enhance its market position in the gene editing industry and obtain access to ERS' CRISPR/Cas9 patent portfolio. These kinds of programs should increase the potential for outsourcing in the field of genome editing and have a beneficial effect on market expansion.  

 

Regional Segment Analysis of the Global Genome Editing Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global genome editing market over the predicted timeframe.

 

Get more details on this report -

Request Free Sample PDF

 

North America is anticipated to hold the largest share of the global genome editing market over the predicted timeframe. The region is expected to continue to be dominant for the anticipated amount of time due to the existence of several biotechnology and pharmaceutical businesses that are focusing on creating genome editing technologies. Due of the robust growth tendency in the biotechnology and pharmaceutical industries, North America leads the genome editing industry. The market is anticipated to rise throughout the study period due to factors including increased R&D costs, product approvals, and technical advancements in genome editing.

 

Asia Pacific is expected to grow at the fastest pace in the global genome editing market during the forecast period. The growing frequency of genetic illnesses and disorders in nations like Australia and India, as well as the growing need for gene editing technologies, are predicted to fuel market expansion in the area. Moreover, funds and investments are being drawn to domestic businesses that offer gene editing services and goods. For example, GenScript introduced its Research-Grade Lentiviral Vector Packaging Service in April 2021 to facilitate gene editing, drug discovery, and cell line creation.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global genome editing market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Merck KGaA
• Cibus Inc.
• Recombinetics
• Sangamo Therapeutics
• Editas Medicine
• Precision BioSciences
• CRISPR Therapeutics
• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc
• Cellectis S.A.
• AstraZeneca
• Takara Bio Inc.
• Horizon Discovery Ltd. (Revvity, Inc.)
• Danaher Corporation
• Transposagen Biopharmaceuticals, Inc.
• Genscript Biotech Corp
• New England Biolabs
• OriGene Technologies, Inc.
• bluebird bio, Inc.
• Lonza
• Thermo Fisher Scientific, Inc  
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In January 2024, Danaher Corporation collaborated with the Innovative Genomics Institute (IGI). This partnership aims to develop CRISPR-based therapies for rare genetic disorders, leveraging Danaher’s diverse technological resources and IGI’s academic expertise.

 

• In November 2023, Cellectis and AstraZeneca entered into a collaboration agreement to accelerate advanced therapeutics development in oncology and immunology.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global genome editing market based on the below-mentioned segments: 

 

Global Genome Editing Market, By Technology

• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Mega nuclease
• Others

 

Global Genome Editing Market, By Delivery Mode

• Ex-vivo
• In-vivo

 

Global Genome Editing Market, By Application

• Genetic Engineering

• Clinical Applications

 

Global Genome Editing Market, By Mode

• Contract
• In-house

 

Global Genome Editing Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa